Elisabet E Manasanch
Overview
Explore the profile of Elisabet E Manasanch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
1228
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Qin L, Moreno Rueda L, Ray U, Mahmud I, Tan L, Lorenzi P, et al.
Blood
. 2025 Feb;
PMID: 39912779
Plasma cell dyscrasias encompass a spectrum from the precursors monoclonal gammopathy of undetermined significance and smoldering myeloma to symptomatic myeloma, but the genes that enable progression and confer poor prognosis...
2.
Moreno Rueda L, Wang H, Akagi K, Dang M, Vora A, Qin L, et al.
Cell Rep Med
. 2025 Jan;
6(2):101925.
PMID: 39855192
Multiple myeloma is a clonal plasma cell (PC) dyscrasia that arises from precursors and has been studied utilizing approaches focused on CD138 cells. By combining single-cell RNA sequencing (scRNA-seq) with...
3.
Szymura S, Wang L, Zhang T, Cha S, Song J, Dong Z, et al.
Nat Commun
. 2024 Aug;
15(1):6874.
PMID: 39128904
Lymphoplasmacytic lymphoma (LPL) is an incurable low-grade lymphoma with no standard therapy. Nine asymptomatic patients treated with a first-in-human, neoantigen DNA vaccine experienced no dose limiting toxicities (primary endpoint, NCT01209871)....
4.
Alzahrani K, Pasvolsky O, Wang Z, Milton D, Tanner M, Bashir Q, et al.
Br J Haematol
. 2024 Mar;
204(5):1944-1952.
PMID: 38448009
The second revision of the International Staging System (R2-ISS) is a simple tool to risk-stratify newly diagnosed multiple myeloma (NDMM) patients. Here, we completed a retrospective analysis to evaluate the...
5.
Mikkilineni L, Natrakul D, Lam N, Manasanch E, Mann J, Weissler K, et al.
Mol Ther
. 2023 Dec;
32(2):503-526.
PMID: 38155568
Multiple myeloma (MM) is a rarely curable malignancy of plasma cells. MM expresses B cell maturation antigen (BCMA). We developed a fully human anti-BCMA chimeric antigen receptor (CAR) with a...
6.
Damron E, Qazilbash M, Fang P, Wu S, Dabaja B, Rondon G, et al.
Transplant Cell Ther
. 2023 Sep;
29(1):37.e1-37.e7.
PMID: 37753818
Primary treatment of multiple myeloma (MM) often involves systemic induction therapy (SIT) followed by autologous stem cell transplantation (ASCT). Radiation therapy (RT) is sometimes used for palliation; however, many practitioners...
7.
Setayesh S, Ndacayisaba L, Rappard K, Hennes V, Moreno Rueda L, Tang G, et al.
NPJ Precis Oncol
. 2023 Sep;
7(1):95.
PMID: 37723227
Multiple myeloma (MM) is accompanied by alterations to the normal plasma cell (PC) proteome, leading to changes to the tumor microenvironment and disease progression. There is a great need for...
8.
Dang M, Wang R, Lee H, Patel K, Becnel M, Han G, et al.
Cancer Cell
. 2023 Jun;
41(6):1032-1047.e4.
PMID: 37311413
Multiple myeloma remains an incurable disease, and the cellular and molecular evolution from precursor conditions, including monoclonal gammopathy of undetermined significance and smoldering multiple myeloma, is incompletely understood. Here, we...
9.
Li N, Lin P, Zuo Z, You M, Shuai W, Orlowski R, et al.
Cancer Med
. 2023 May;
12(13):14293-14304.
PMID: 37212518
Background: Mutations in the RAS-MAPK pathway, such as KRAS, NRAS, and BRAF, are known as high-risk factors associated with poor prognosis in patients with various cancers, but studies in myeloma...
10.
Chiu C, Mustafayev K, Lee H, Manasanch E, Yepez Guevara E, Torres H
Leuk Lymphoma
. 2023 Mar;
64(4):900-903.
PMID: 36883878
No abstract available.